Research study · Biomedicines · 2026
Phospholipid-Based Delivery System Optimizes the Solubility and Systemic Exposure of Palmitoylethanolamide and Supports Clinical Benefits in Chronic Neuropathic Low Back Pain
Verified on PubMed Oxford CEBM Level 1B: Randomized Controlled Trial
A 2026 randomized controlled trial in Biomedicines tested palmitoylethanolamide in low back pain. The supplement helped. People who took it reported less pain, less trouble with daily activities, better sleep and a better quality of life than people who took the dummy pill, and many of them needed fewer pain medicines. This formulation may allow.
In plain language
Study overview
A group of adults with long-lasting lower back pain that has a nerve-related component took part in a study. They were given a daily supplement made from a natural body fat molecule, packaged in a form designed to be absorbed better, or a dummy pill, for eight weeks alongside their usual care.
Findings
The supplement helped. People who took it reported less pain, less trouble with daily activities, better sleep and a better quality of life than people who took the dummy pill, and many of them needed fewer pain medicines. The supplement caused only mild side effects, and no serious problems were reported.
Explore Dr. Caplan's interactive tool detailing cytochrome P450 pathways, clinical titration intervals, and physician surveillance rules.
The deeper readScientific analysis
Background: Chronic neuropathic low back pain (LBP) is a prevalent health condition and difficult to treat. Conventional therapies often provide limited relief and raise safety concerns. Supplemental palmitoylethanolamide (PEA), an endogenous fatty acid amide with analgesic and anti-inflammatory properties, has shown benefits in neuropathic pain, but its application as a supportive strategy has been limited by poor oral bioavailability. Objectives: This study aimed to investigate a phospholipid-based palmitoylethanolamide formulation (PEA-PL, Cronilief™), developed using Phytosome™ delivery technology, with respect to solubility optimization, systemic exposure, and associated clinical effects in individuals with chronic neuropathic LBP. Methods: PEA-PL solubility was assessed in fasted-state simulated intestinal fluid and compared with unformulated PEA. Plasma PEA concentrations were evaluated in healthy volunteers after 2 weeks of supplementation with unformulated PEA (300 mg/day) or PEA-PL (300 or 600 mg/day). Clinical efficacy was assessed in a double-blind, placebo-controlled randomized trial in which 120 adults with neuropathic LBP received PEA-PL 600→300 mg (n = 40), PEA-PL 450 mg (n = 40), or placebo (n = 40), daily for 8 weeks in addition to Standard of Care. Primary outcomes were effects on neuropathic pain (Douleur Neuropathique 4, DN4) and its intensity (Numeric Pain Rating Scale, NPRS). Secondary outcomes included effect on functional disability (Oswestry Disability Index, ODI), sleep quality (Pittsburgh Sleep Quality Index, PSQI), quality of life (QoL) (SF-12), and concomitant analgesic use. Safety was monitored throughout the 8-week supplementation period. Results: PEA-PL increased PEA solubility approximately eight-fold and resulted in higher plasma PEA concentrations than unformulated PEA. Both PEA-PL regimens significantly improved pain, functional disability, sleep, and QoL outcomes versus placebo (all p < 0.0001), with greater effects for the 600→300 mg regimen. Analgesic discontinuation occurred more frequently in PEA-PL groups (65–70%). Supplementation was well tolerated. Conclusions: A phospholipid-based (Phytosome™) PEA formulation (Cronilief™) was developed and associated with optimized systemic exposure and clinically meaningful reductions in pain severity and functional disability in individuals with chronic neuropathic LBP.
The paper
Citation
Khan A, Rabbani F, Kanwal A, Shafiq A, Ujjan I, Vellaccio A, et al. Phospholipid-Based Delivery System Optimizes the Solubility and Systemic Exposure of Palmitoylethanolamide and Supports Clinical Benefits in Chronic Neuropathic Low Back Pain. Biomedicines (2026). PubMed 41751279 · DOI
Limitations the authors noted
Both studies were described by the authors as exploratory. Pharmacokinetic study had small sample (11 completers) in healthy volunteers, not a definitive pharmacokinetic characterization. Single-center efficacy trial limits generalizability. Follow-up limited to 8 weeks; long-term efficacy and safety not assessed. No neuroinflammatory or pain-related biomarkers included. Co-administered standard-of-care analgesics (paracetamol, NSAIDs) and supportive therapies allowed, complicating attribution. Industry co-authorship and manufacturer-supplied product and placebo. Protocol registered but no formal power calculation; sample size based on prior studies.
In practice
Why this matters
This formulation may allow clinicians to offer a better-tolerated option for patients who struggle with standard pain medications or have not found relief from conventional treatments.
Frequently asked questions
Clinical Questions & Answers
What were the primary clinical findings regarding Palmitoylethanolamide and Insomnia?
The supplement helped. People who took it reported less pain, less trouble with daily activities, better sleep and a better quality of life than people who took the dummy pill, and many of them needed fewer pain medicines. The supplement caused only mild side effects, and no serious problems were reported.
What study limitations or clinical safeguards should patients keep in mind?
Both studies were described by the authors as exploratory. Pharmacokinetic study had small sample (11 completers) in healthy volunteers, not a definitive pharmacokinetic characterization. Single-center efficacy trial limits generalizability.
Browse related research
Condition: Insomnia Condition: Low back pain Condition: Pain Topic: Palmitoylethanolamide
Related on CED Clinic
Back to Daily Research and Patient Questions
Reviewed by Dr. Caplan on October 20, 2026.
This page is general education about a published study. It is not medical advice and does not create a doctor-patient relationship. For care specific to you, book a consultation.
